Acquired by Clayton, Dubilier & Rice and TPG in Oct 2022
CVET - Covetrus, Inc.
NASDAQ
->
Healthcare
->
Health Information Services
Portland,
United States
Type: Equity
CVET price evolution
CVET
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $87 | $117 | $183 | $187 |
| Short term investments | ||||
| Net receivables | $656 | $627 | $555 | $568 |
| Inventory | $587 | $630 | $583 | $552 |
| Total current assets | $1378 | $1417 | $1351 | $1351 |
| Long term investments | $45 | $48 | $49 | $96 |
| Property, plant & equipment | $287 | $285 | $281 | $247 |
| Goodwill & intangible assets | $1648 | $1681 | $1686 | $1726 |
| Total noncurrent assets | $2020 | $2053 | $2059 | $2069 |
| Total investments | $45 | $48 | $49 | $96 |
| Total assets | $3398 | $3470 | $3410 | $3420 |
| Current liabilities | ||||
| Accounts payable | $446 | $507 | $442 | $428 |
| Deferred revenue | ||||
| Short long term debt | $66 | $52 | $32 | $46 |
| Total current liabilities | $733 | $762 | $698 | $714 |
| Long term debt | $983 | $995 | $1014 | $1027 |
| Total noncurrent liabilities | $1138 | $1158 | $1178 | $1181 |
| Total debt | $1049 | $1047 | $1046 | $1073 |
| Total liabilities | $1871 | $1920 | $1876 | $1895 |
| Shareholders' equity | ||||
| Retained earnings | -$1087 | -$1083 | -$1081 | -$1078 |
| Other shareholder equity | -$110 | -$81 | -$79 | -$80 |
| Total shareholder equity | $1505 | $1528 | $1511 | $1502 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $183 | $290 | $130 | $23.32 |
| Short term investments | ||||
| Net receivables | $555 | $574 | $493 | $480.01 |
| Inventory | $583 | $530 | $636 | $564.16 |
| Total current assets | $1351 | $1431 | $1340 | $1086.61 |
| Long term investments | $49 | $90 | $47 | $119.95 |
| Property, plant & equipment | $281 | $233 | $177 | $68.55 |
| Goodwill & intangible assets | $1686 | $1742 | $1797 | $957.98 |
| Total noncurrent assets | $2059 | $2065 | $2021 | $1146.48 |
| Total investments | $49 | $90 | $47 | $119.95 |
| Total assets | $3410 | $3496 | $3361 | $2233.08 |
| Current liabilities | ||||
| Accounts payable | $442 | $405 | $520 | $441.45 |
| Deferred revenue | ||||
| Short long term debt | $32 | $1 | $62 | $0.68 |
| Total current liabilities | $698 | $691 | $829 | $572.56 |
| Long term debt | $1014 | $1068 | $1125 | $23.53 |
| Total noncurrent liabilities | $1178 | $1232 | $1266 | $74.47 |
| Total debt | $1046 | $1069 | $1187 | $24.2 |
| Total liabilities | $1876 | $1923 | $2095 | $647.03 |
| Shareholders' equity | ||||
| Retained earnings | -$1081 | -$1027 | -$1040 | $1575.8 |
| Other shareholder equity | -$79 | -$66 | -$86 | -$82.21 |
| Total shareholder equity | $1511 | $1537 | $1256 | $1493.62 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1217 | $1148 | $1122 | $1162 |
| Cost of revenue | $988 | $923 | $910 | $946 |
| Gross Profit | $229 | $225 | $212 | $216 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $225 | $219 | $219 | $220 |
| Total operating expenses | $225 | $219 | $219 | $220 |
| Operating income | $4 | $6 | -$7 | -$4 |
| Income from continuing operations | ||||
| EBIT | $4 | $8 | -$4 | -$6 |
| Income tax expense | $1 | $3 | -$7 | -$10 |
| Interest expense | $7 | $7 | $6 | $8 |
| Net income | ||||
| Net income | -$4 | -$2 | -$3 | -$4 |
| Income (for common shares) | -$4 | -$2 | -$3 | -$4 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4575 | $4339 | $3976 | $3777.99 |
| Cost of revenue | $3717 | $3541 | $3227 | $3093.88 |
| Gross Profit | $858 | $798 | $749 | $684.11 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $881 | $867 | $808 | $538.47 |
| Total operating expenses | $881 | $867 | $1746 | $547.01 |
| Operating income | -$23 | -$69 | -$997 | $137.1 |
| Income from continuing operations | ||||
| EBIT | -$22 | $21 | -$970 | $137.89 |
| Income tax expense | -$7 | -$7 | $37.03 | |
| Interest expense | $32 | $47 | $56 | $3 |
| Net income | ||||
| Net income | -$54 | -$19 | -$1019 | $100.86 |
| Income (for common shares) | -$54 | -$19 | -$1019 | $100.86 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Net income | -$4 | -$2 | -$3 | -$4 |
| Operating activities | ||||
| Depreciation | $48 | $48 | $51 | $49 |
| Business acquisitions & disposals | -$18 | -$81 | ||
| Stock-based compensation | $10 | $13 | $7 | $14 |
| Total cash flows from operations | -$6 | -$33 | $44 | $59 |
| Investing activities | ||||
| Capital expenditures | -$15 | -$11 | -$21 | -$14 |
| Investments | ||||
| Total cash flows from investing | -$15 | -$29 | -$21 | -$95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3 | $2 | $4 | $4 |
| Net borrowings | -$30 | |||
| Total cash flows from financing | -$1 | -$5 | -$29 | -$3 |
| Effect of exchange rate | -$8 | $1 | $2 | -$4 |
| Change in cash and equivalents | -$30 | -$66 | -$4 | -$43 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$54 | -$19 | -$1019 | $100.86 |
| Operating activities | ||||
| Depreciation | $200 | $190 | $176 | $64.1 |
| Business acquisitions & disposals | -$81 | $49 | -$26 | -$8.17 |
| Stock-based compensation | $46 | $40 | $46 | $7.05 |
| Total cash flows from operations | $102 | $53 | $103 | $157.9 |
| Investing activities | ||||
| Capital expenditures | -$59 | -$54 | -$39 | -$21.2 |
| Investments | ||||
| Total cash flows from investing | -$140 | -$5 | -$65 | -$29.37 |
| Financing activities | ||||
| Dividends paid | -$6 | -$1174 | -$10 | |
| Sale and purchase of stock | $8 | $10 | $5 | |
| Net borrowings | -$30 | -$122 | $1153 | -$2.1 |
| Total cash flows from financing | -$66 | $104 | $66 | -$119.69 |
| Effect of exchange rate | -$3 | $8 | $3 | -$2.17 |
| Change in cash and equivalents | -$107 | $160 | $107 | $6.67 |
News
|
Covetrus (CVET) Q2 Earnings Match Estimates
Zacks via Yahoo Finance
4 Aug 2022
|
|
Covetrus going private in $4 billion deal
MarketWatch
25 May 2022
|
|
CD&R, TPG Take Covetrus Private In $4B Deal
Benzinga via Yahoo Finance
25 May 2022
|
|
Raymond James View Skewed Scenarios On Absent Supportive Bid For This Animal Health Stock
Benzinga via Yahoo Finance
23 May 2022
|
|
TPG Joins Clayton Dubilier in Covetrus Buyout Offer
The Wall Street Journal
21 May 2022
|
|
Is It Time To Consider Buying Covetrus, Inc. (NASDAQ:CVET)?
Simply Wall St. via Yahoo Finance
21 May 2022
|
|
Covetrus (CVET) Q1 Earnings Surpass Estimates
Zacks via Yahoo Finance
6 May 2022
|
|
Further weakness as Covetrus (NASDAQ:CVET) drops 11% this week, taking three-year losses to 56%
Simply Wall St. via Yahoo Finance
28 Apr 2022
|
|
F5 Networks (FFIV) Q2 Earnings and Revenues Beat Estimates
Zacks via Yahoo Finance
26 Apr 2022
|
|
Hello Group Inc. Sponsored ADR (MOMO) Surges 51.5%: Is This an Indication of Further Gains?
Zacks via Yahoo Finance
17 Mar 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 139.84M |
| Revenue | $4.65B |
|---|---|
| EBITDA | $198.00M |
| EBIT | $2.00M |
| Net Income | -$13.00M |
| Revenue Q/Q | 2.35% |
| Revenue Y/Y | 2.42% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 11.55 |
| Cash/Share | 0.62 |
| EPS | -$0.09 |
|---|---|
| ROA | -0.38% |
| ROE | -0.86% |
| Debt/Equity | 1.24 |
|---|---|
| Net debt/EBITDA | 9.01 |
| Current ratio | 1.88 |
| Quick ratio | 1.08 |